FacebookTwitterGoogle+RedditEmail

Spinning Suicide Statistics

by MARTHA ROSENBERG

It’s been a busy year for pharma, creating new diseases to make healthy people take pills, reformulating existing drugs to win “new! improved!” patents, hiring high heel wearing reps to intercept the doc before ailing patients–and fear mongering suicide statistics to revive waning antidepressant prescriptions.

Long before the New York Times reported this month that youth suicides were up 8% from 2003 to 2004 and experts blamed an “antidepressant deficiency” big pharma was trying to plant the story.

There’s too much money in diagnosing children with major psychiatric illnesses and keeping them on psychotropic drugs their whole lives to let a little thing like the black box warnings the FDA imposed on antidepressants for children in 2004 ruin sales.

After all this is a nation that believes that children are born with a Ritalin deficiency, insomnia is Ambien deficiency and old age is hormone deficiency. Why shouldn’t pharmacology trump biology with suicide statistics as well?

Last year an article in the June issue of PLoS Medicine set the stage.

Lead author Dr. Julio Licinio, a consultant to Prozac-maker Eli Lilly, found the U.S. suicide rate “dropped steadily over 14 years as sales of the antidepressant [Prozac] rose.”

It was followed by an article in April in the Archives of General Psychiatry by four representatives of a private “drug development services” company called Quintiles Transnational and four other authors expressing concerns that “the number of children and teenagers who were prescribed antidepressants has decreased significantly” underlining “the importance of presenting a fair balance within the media.” (“Impact of Publicity Concerning Pediatric Suicidality Data on Physician Practice Patterns in the United States”)

And in February a MedPage Today article actually scooped the New York Times with the headline, “Teen Suicide Spike Linked to SSRI Black Box.”

Black box warnings create a barrier to treatment “by scaring young people and parents away from care,” said David Shern, Ph.D., president of Mental Health America, reported to have accepted $3.8 million from pharmaceutical companies in 2005, in a statement when the article broke.

Charles Nemeroff, M.D., Ph.D., of Emory University School of Medicine took it a step further.

“The concerns about antidepressant use in children and adolescents have paradoxically resulted in a reduction in their use, and this has contributed to increased suicide rates,” he told reporters. Dr. Nemeroff has links to Eli Lilly, Pfizer, Wyeth-Ayerst, Pharmacia-Upjohn and five other drug makers according to published reports.

Unfortunately for pharma, when the New York Times broke the story it had a short shelf life.

The rise in suicides among ages 10 to 24 in 2003 to 2004 stood. But the charge that the rise was due to a drop-off in antidepressant prescriptions, especially selective serotonin reuptake inhibitors (SSRIs) like Prozac, which came from an article in the September American Journal of Psychiatry, promptly fell on its head.

It turned out the drop in SSRI prescriptions that “caused” the suicide rise occurred the following year. In most of the year cited, SSRI prescriptions actually “rose an average of just over 10 percent” for those 18 and under according to Psychiatric News and “the number of prescriptions peaked in March 2004.”

Meanwhile preliminary Centers for Disease Control and Prevention statistics from the year that would have been influenced by a drop in SSRI prescription that occurred–2005–do not show deaths up, though they have not been broken into category.

Asked about the 180% turnaround in facts which meant the suicide rise was not caused by SSRI prescription drop-offs and possibly caused by SSRIs themselves, vindicating the FDA’s black boxes, the article’s lead author Robert D. Gibbons, Ph.D., a professor of biostatistics and psychiatry at the University of Illinois at Chicago, did not sound the statistician.

“This study was suggestive, that’s what we’re saying,” Dr. Gibbons told the Times in a follow-up story–“Early Evidence on the Effects of Regulators’ Suicidality Warnings on SSRI Prescriptions and Suicide in Children and Adolescents” is suggestive? try conclusive–and should piggyback off previous studies that showed the links better.

Then why publish it?

There were other question marks about the American Journal of Psychiatry article too–not counting Pfizer’s financial contribution and Dr. Gibbons link to Wyeth Pharmaceuticals.

What if the suicides aren’t about SSRIs at all but the growing popularity of treating children with antipsychotic drugs?

“I would be absolutely certain that the increase is not because kids are not being treated,” says David Healy, M.D., a psychiatrist at the University of Cardiff and early critic of SSRIs. “They may not be getting SSRIs, but they are getting psychotropics,” he says and, “the antipsychotic ‘mood stabilizers’ have just as great an increase in suicide risk as antidepressants–if not greater.”

Pharma is probably working on a new round of articles on the topic right now.

 

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

More articles by:

CounterPunch Magazine

minimag-edit

bernie-the-sandernistas-cover-344x550

zen economics

February 22, 2017
Mike Whitney
Liberals Beware: Lie Down With Dogs, Get Up With Fleas
John Grant
On Killers and Bullshitters*
Peter Linebaugh
Catherine Despard, Abolitionist
Patrick Cockburn
The Bitter Battle for Mosul
Ted Rall
Sue the Bastards? It’s Harder Than You Think
Yoav Litvin
The Emergence of the Just Jew
Kim Scipes
Strategic Thinking and Organizing Resistance
Norman Pollack
Mar-a-Lago, Ideological Refuge: Berchtesgaden, II
Fred Donner
Nixon and the Chennault Affair: From Vietnam to Watergate
Carl Kandutsch
Podesta vs. Trump
Ike Nahem
To the Memory of Malcolm X: Fifty Years After His Assassination
Jesse Jackson
Trump’s Tough Talk Won’t Fix Chicago
Paul Donnelly
Betsy DeVos and the War on Public Education
Ebony Slaughter-Johnson
The End of an Alliance for Police Reform
Richard Lawless
Wall Street Demanded the Nuclear Option and the Congress Delivered
Liaquat Ali Khan
Yes, Real Donald Trump is a Muslim!
Ryan LaMothe
“Fire” and Free Speech
CounterPunch News Service
Bloody Buffalo Billboards
February 21, 2017
Sharmini Peries - Michael Hudson
Finance as Warfare: the IMF Lent to Greece Knowing It Could Never Pay Back Debt
CJ Hopkins
Goose-stepping Our Way Toward Pink Revolution
John Wight
Firestarter: the Unwelcome Return of Tony Blair
Roger Harris
Lenin Wins: Pink Tide Surges in Ecuador…For Now
Shepherd Bliss
Japanese American Internment Remembered, as Trump Rounds Up Immigrants
Boris Kagarlitsky
Trump and the Contradictions of Capitalism
Robert Fisk
The Perils of Trump Addiction
Deepak Tripathi
Theresa May: Walking the Kingdom Down a Dark Alley
Sarah Anderson
To Save Main Street, Tax Wall Street
Howard Lisnoff
Those Who Plan and Enjoy Murder
Franklin Lamb
The Life and Death Struggle of the Children of Syria
Binoy Kampmark
A Tale of Two Realities: Trump and Israel
Kim C. Domenico
Body and Soul: Becoming Men & Women in a Post-Gender Age
Mel Gurtov
Trump, Europe, and Chaos
Stephen Cooper
Steinbeck’s Road Map For Resisting Donald Trump
February 20, 2017
Bruce E. Levine
Humiliation Porn: Trump’s Gift to His Faithful…and Now the Blowback
Melvin Goodman
“Wag the Dog,” Revisited
Robert Hunziker
Fukushima: a Lurking Global Catastrophe?
David Smith-Ferri
Resistance and Resolve in Russia: Memorial HRC
Kenneth Surin
Global India?
Norman Pollack
Fascistization Crashing Down: Driving the Cleaver into Social Welfare
Patrick Cockburn
Trump v. the Media: a Fight to the Death
Susan Babbitt
Shooting Arrows at Heaven: Why is There Debate About Battle Imagery in Health?
Matt Peppe
New York Times Openly Promotes Formal Apartheid Regime By Israel
David Swanson
Understanding Robert E. Lee Supporters
Michael Brenner
The Narcissism of Donald Trump
Martin Billheimer
Capital of Pain
FacebookTwitterGoogle+RedditEmail